Skip to main content
2022 Guide to Patient Support Services

Pharmacyclics & Janssen Biotech

2022 Oncology Guide to Patient Support Services

Pharmacyclics and Janssen Biotech: By Your Side Patient Support Program


Pharmacyclics and Janssen Biotech offer the By Your Side patient support program to assist patients while taking Imbruvica (Table).

By Your Side

This program offers personalized support to help patients access and stay on track with Imbruvica, including:

  • Connections with Field Access Specialists who work with your office to help patients navigate insurance reimbursement
  • By Your Side Ambassadors who will call your patient within 1 business day of enrollment and provide individualized support and financial assistance options
  • Dose Exchange Program
  • Resources and tools to support patients throughout the treatment journey.

Click here to learn more or to enroll your patient in the By Your Side patient support program, or call 888-968-7743.

Affording Treatment

By Your Side Ambassadors connect your patients with insurance specialists to learn about access to Imbruvica and find affordability support options. Eligible patients with commercial insurance may be able to pay as little as $10 per prescription of Imbruvica.

For uninsured patients, the Janssen-affiliated Johnson & Johnson Patient Assistance Foundation, which is an independent, nonprofit organization, may offer assistance with accessing Imbruvica for eligible patients who qualify based on financial need. You can check eligibility at

For patients with federally funded Medicare, Medicaid, or commercial insurance, financial assistance may be available from independent charitable organizations.

Dose Exchange Program

This program facilitates a dose reduction if you decide to adjust your patient’s dose before they have finished their current pack of Imbruvica. To be eligible, patients must:

  • Have remaining pills from a current prescription for an FDA-approved indication for Imbruvica
  • Return their remaining pills. Instructions for return will be provided with a preaddressed envelope for the patient to return the unused quantity of previous strength.

Click here to learn more or to enroll your patient in the Dose Exchange Program.

TABLE Pharmacyclics Oncology Drug

Patient support programs

Imbruvica (ibrutinib)
Treatment of adults with mantle-cell lymphoma after ≥1 therapies; treatment of adults with CLL or with SLL, including CLL or SLL with 17p deletion; treatment of adults with Waldenström’s macroglobulinemia; treatment of marginal-zone lymphoma in adults who require systemic therapy, after ≥1 anti–CD20-based therapies; treatment of adults with chronic graft-versus-host disease, after failure of ≥1 lines of systemic therapy
Patient support programs

CLL indicates chronic lymphocytic leukemia; SLL, small lymphocytic lymphoma.

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"